Accelsiors is a global, full-service, independently owned Clinical Research Organization (CRO) established in 2002. Our global reach reaches across 40 countries, counting 27 offices.
At Accelsiors, we pride ourselves in our scientifically driven approach, which ensures compliance with all regulatory standards, all whilst managing clinical trials across all phases and therapeutic areas. Supporting clients from the very early stage of drug discovery and development, through to product registration is what we are best at. We utilize advanced clinical research techniques, and our highly qualified, scientific team is committed to delivering high quality services, innovative methodologies and approaches, and cost-effective solutions. Flexibility and expertise of industry leaders are the very cornerstone of Accelsiors, as we drive the success of clinical research projects worldwide.
Accelsiors Phase I Unit in Thessaloniki, Greece, is the newest addition to the corporation, as we expand our horizons to new and improved clinical trials. This state-of-the-art Phase I unit is designed to cater to the ever-evolving needs of early phase clinical research. Our facility is strategically located within hospital grounds, ensuring easy access to tertiary care, as well as niche patient populations. Being the only legally recognized Phase I Unit in Greece, Accelsiors is strategically positioned to conduct first-in-human (FIH) trials, backed by our strategic position within the Papageorgiou Hospital grounds, staff expertise, and global experience.
Thessaloniki Accelsiors Phase I Unit offers a unique environment which supports efficient study start-up through our detailed legal services and contractual frameworks. Our partnership with the Papageorgiou Hospital guarantees access to top-tier medical staff and advanced monitoring capabilities, which is the perfect grounds for conducting any complex early phase study.
Our commitment is to delivering exceptional patient care and data quality through Accelsiors innovative methodologies and integrated proprietary technologies. Utilizing out global Accelsiors network, and local Accelsiors knowledge, we guarantee faster recruitment of niche patient populations, all whilst navigating the regulatory requirements effectively. The The Thessaloniki Phase I Unit now enhances our service offerings, and it also strengthens our dedication to being a forerunner in clinical research.
Join us in our journey of accelerating the path to new therapies, and bringing them to patients worldwide.
Whether you have questions, or want to explore partnership opportunities, get in touch! Our team is committed to providing timely responses to all inquiries.
